

Lumosa Therapeutics Co., Ltd.

Meeting Notice of 2024 Annual Shareholders' Meeting

【Summary Translation】

The 2024 Annual Shareholders' Meeting (the "Meeting") of Lumosa Therapeutics Co., Ltd. (the "Company") will be convened at 9:00 a.m., May 2, 2024 (Thu) at the Nankang Software Incubator, with an address of Rm. 423, 4F., Building E, No. 19-11, Sanchong Rd., Nangang Dist., Taipei.

1. The agenda for the Meeting is as follows:

A. Report Items

- (1) 2023 Business Reports.
- (2) 2023 Audit Committee's Review Report.
- (3) Execution Report on the Robust Operational Plan for the 2021 Cash Capital Increase through New Share Issuances
- (4) Report on the Execution of Private Placement
- (5) Report on Accumulated Deficits Reaching Half of Paid-in Capital
- (6) The 2023 Directors' Remuneration

B. Proposed Resolutions

- (1) Please Approve the 2023 Business Report and Financial Statements.
- (2) Please Approve the Proposed 2023 Deficit Compensation Plan.

C. Discussions

- (1) Please Discuss the Proposal to Amend Certain Provisions of the "Articles of Incorporation."
- (2) Please Discuss the Proposal to Amend Certain Provisions of the "Rules of Procedure for Shareholders' Meetings."

- (3) Please Discuss the Proposal to Issue New Shares through Private Placement for Cash Capital Increase

D. Directors Election

- (1) Please Conduct the Election of the Directors

E. Other Business and Special Motions

- (1) Please Discuss the Proposal to Lift Non-competition Restrictions on Directors.

F. Questions and Motions

G. Adjournment

- 2. The proposal for the distribution of 2023 profits has been resolved by the Board of Directors meeting to not distribute dividends**
- 3. The Company propose to issue new common shares by private placement in cash. Shareholders may visit MOPS at <http://mops.twse.com.tw> for more information.**
- 4. The Company adopted the candidate nomination system for electing the Nine directors (including Four independent directors).**

The list of the nominated candidates is as follows:

Director candidates:

Jung Chin Lin Representative of Center Laboratories, Inc.

Wann Lai Cheng Representative of Center Laboratories, Inc.

BioEngine Technology Development Inc.

Shun Cheng Pharmaceutical Co

Hsueh Ling Wang

Independent Director candidates:

Chih Hsiung Wu

Hai I Ma

Chih Yung Chin

Hsin-Jung Lin

Please refer to MOPS at <http://mops.twse.com.tw> for the educational background and experience relevant information.

5. If the Company decides to hold a meeting under Article 172 of the Company Law, electronic files will be posted to the Market Observation Post System at <https://emops.twse.com.tw>. Please select "Shareholders' Meetings" under the "Electronic Books" tab, enter the year, and click "GO" to find the meeting files corresponding to Company code.
6. Pursuant to Article 165 of the Company Act, the Company hereby closes the share transfer registration from March 4, 2024 to May 2, 2024.
7. Please find enclosed the "Notice of Attendance" and "Proxy Statement." If you intend to personally attend the meeting, please sign or place your seal in the "Registration Card" column. Shareholders may sign or place their seal in the "Proxy Statement" column to appoint a proxy to attend the meeting on his or her behalf and execute power of attorney in writing. Please fill in the "Proxy Statement" and deliver to the Company's stock agency, Grand Fortune Securities Co., Ltd. Transfer Agent, 5 days prior to the meeting date.
8. Shareholders may exercise his/her/its voting rights by way of electronic transmission during the period from April 2, 2024 to April 29, 2024. Please log in the "Stockvote" (<https://www.stockvote.com.tw>) of Taiwan Depository & Clearing Corporation (TDCC) and vote in.
9. The Transfer Agency Department of Capital Securities Corporation is the proxy tallying and verification institution for this Annual meeting.
10. It is highly appreciated that you handle the matters accordingly.

To Shareholder

Board of Directors

Lumosa Therapeutics Co., Ltd.